In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
Open Access
- 15 August 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (4), 1145-1150
- https://doi.org/10.1182/blood-2004-01-0388
Abstract
Patients with acute myeloid leukemia (AML) harboring internal tandem duplication mutations of the FLT3 receptor (FLT3/ITD mutations) have a poor prognosis compared to patients lacking such mutations. Incorporation of FLT3 inhibitors into existing chemotherapeutic regimens has the potential to improve clinical outcomes in this high-risk group of patients. CEP-701, an indolocarbazole-derived selective FLT3 inhibitor, potently induces apoptosis in FLT3/ITD-expressing cell lines and primary leukemic blasts. We conducted a series of in vitro cytotoxicity experiments combining CEP-701 with chemotherapy using the FLT3/ITD-expressing cell lines MV4-11 and BaF3/ITD as well as a primary blast sample from a patient with AML harboring a FLT3/ITD mutation. CEP-701 induced cytotoxicity in a synergistic fashion with cytarabine, daunorubicin, mitoxantrone, or etoposide if used simultaneously or immediately following exposure to the chemotherapeutic agent. In contrast, the combination of pretreatment with CEP-701 followed by chemotherapy was generally antagonistic, particularly with the more cell cycle-dependent agents such as cytarabine. This effect appears to be due to CEP-701 causing cell cycle arrest. We conclude that in FLT3/ITD-expressing leukemia cells, CEP-701 is synergistic with standard AML chemotherapeutic agents, but only if used simultaneously with or immediately following the chemotherapy. These results should be considered when designing trials combining chemotherapy with each of the FLT3 inhibitors currently in clinical development. (Blood. 2004; 104:1145-1150)This publication has 29 references indexed in Scilit:
- Novel FLT3 tyrosine kinase inhibitorsExpert Opinion on Investigational Drugs, 2003
- FLT3: ITDoes matter in leukemiaLeukemia, 2003
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitorLeukemia, 2001
- Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemiaBritish Journal of Haematology, 2001
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 1999
- Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the productLeukemia, 1998
- Flt3high and Flt3low CD34+Progenitor Cells Isolated From Human Bone Marrow Are Functionally DistinctBlood, 1998
- STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.Proceedings of the National Academy of Sciences of the United States of America, 1994